NEOGENOMICS INC

Insider Trading Plans

During the quarter ended March 31, 2024, no director or Section 16 officer adopted, modified, orterminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408(a) of Regulation S-K).

Disclosure Pursuant to Item 5.02 of Form 8-K -Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported on the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 18, 2024, Melody Harris, formerly the Company's President, Enterprise Operations now serves as the Company's Chief Operations Officer and President, Informatics. In addition, Warren Stone, formerly the Company's President, Clinical Services now serves as the Company's Chief Commercial Officer. In connection with her new role, effective April 29, 2024, Ms. Harris’ new base salary will be $575,000 per year, with annual review and adjustment at the discretion of the Board or the Culture and Compensation Committee of the Board (the “Compensation Committee”), an annual incentive cash bonus of 60% of annual salary and an annual equity-based target award of $1,750,000, each based on the achievement of the Company’s corporate objectives and Ms. Harris’ individual objectives, in each case, as established by the Board or the Compensation Committee. As part of this increased target for 2024 specifically, on May 2, 2024, Ms. Harris will receive an incremental equity grant of $500,000 comprised of stock options, restricted stock units, and performance share units. In connection with his new role, effective April 29, 2024, Mr. Stone’s new base salary will be $580,000 per year, with annual review and adjustment at the discretion of the Board or the Compensation Committee, an annual incentive cash bonus of 65% of annual salary and an annual equity-based target award of $2,000,000, each based on the achievement of the Company’s corporate objectives and Mr. Stone’s individual objectives, in each case, as established by the Board or the Compensation Committee. As part of this increased target for 2024 specifically, on May 2, 2024, Mr. Stone will receive an incremental equity grant of $750,000 comprised of stock options, restricted stock units and performance share units.

In addition, as previously announced, the position of President, Advanced Diagnostics, formerly held by Vishal Sikri, was eliminated effective April 29, 2024.